Cardiff Oncology Full Year 2024 Earnings: Beats Expectations [Yahoo! Finance]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
US$0.95 loss per share (further deteriorated from US$0.93 loss in FY 2023). NasdaqCM:CRDF Earnings and Revenue History March 1st 2025 All figures shown in the chart above are for the trailing 12 month (TTM) period Cardiff Oncology Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 3.2%. Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 11% from a week ago. Risk Analysis You still need to take note of risks, for example - Cardiff Oncology has 5 warning signs (and 4 which don't sit too well with us) we think you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025GlobeNewswire
- Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor ConferenceGlobeNewswire
- Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business UpdateGlobeNewswire
CRDF
Earnings
- 11/6/25 - Beat
CRDF
Sec Filings
- 11/6/25 - Form 8-K
- 11/6/25 - Form 10-Q
- CRDF's page on the SEC website